Expert Summarizes State of CAR T-Cell Therapy in Hematologic Malignancies – OncLive
OncLive |
Expert Summarizes State of CAR T-Cell Therapy in Hematologic Malignancies
OncLive Conversely, patients with chronic lymphocytic leukemia (CLL) have had comparatively lower response rates, said Alfred L. Garfall, MD, who discussed the role of CAR T-cell therapies in hematologic malignancies at the 2017 International Congress on … |
